NFE2L2 and cancer: However, although ITCs can trigger the activation of NRF2 dependent genes, it is believed that excessive activation of NRF2 is associated with tumor progression and increased resistance to chemotherapeutics, indicating the complicated roles of ITC in cancer (Ernst et al., 2011).